<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144348</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1653-P102</org_study_id>
    <nct_id>NCT04144348</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure</brief_title>
  <official_title>A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653,&#xD;
      a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy&#xD;
      adults (18 to 49 years of age) and 3 dose levels in children (12 to 59 months of age) with&#xD;
      serologic evidence of prior exposure. The safety profile of the adult cohort will permit&#xD;
      enrollment of the pediatric cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Parallel for the Adult Cohort, followed by Sequential Assignment for the Pediatric Cohort</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Observer blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Solicited Local and Systemic Adverse Reactions (ARs)</measure>
    <time_frame>up to 7 days after each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with Unsolicited Adverse Events (AEs)</measure>
    <time_frame>up to 28 days after each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with Serious Adverse Events (SAEs) and Medically-Attended AEs</measure>
    <time_frame>Up to 1 year after the last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of Serum Anti-hMPV and Anti-PIV3 Neutralizing Antibodies</measure>
    <time_frame>Day 29, 57, 85, and 224, for adults; Day 29 and 85, for pediatric participants</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of Post-Baseline/Baseline Titers of Serum Anti-hMPV and Anti-PIV3 Neutralizing Antibodies</measure>
    <time_frame>Day 29, 57, 85, and 224, for adults; Day 29 and 85, for pediatric participants</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥2-Fold and ≥4-Fold Increases in Serum Anti-hMPV or Anti-PIV3 Neutralizing Antibody Titer from Baseline</measure>
    <time_frame>Day 29, 57, 85, and 224, for adults; Day 29 and 85, for pediatric participants</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Human Metapneumovirus and Human Parainfluenza Infection</condition>
  <arm_group>
    <arm_group_label>mRNA-1653, Adult participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1653 Pediatric participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 of 3 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Adult participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Pediatric participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1653</intervention_name>
    <description>sterile liquid for injection</description>
    <arm_group_label>mRNA-1653 Pediatric participants</arm_group_label>
    <arm_group_label>mRNA-1653, Adult participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sterile liquid for injection</description>
    <arm_group_label>Placebo, Adult participants</arm_group_label>
    <arm_group_label>Placebo, Pediatric participants</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 to 49 years of age and children 12 to 59 months of age at the time of&#xD;
             consent who, in the opinion of the Investigator, are in good health based on review of&#xD;
             medical history and screening physical examination&#xD;
&#xD;
          -  Adult participant or parent(s)/legal guardian(s) has provided written informed consent&#xD;
             for participation in this trial, including all evaluations and procedures as specified&#xD;
             by this protocol&#xD;
&#xD;
          -  Screening laboratory values Grade ≤1&#xD;
&#xD;
        Specific inclusion criteria for adults 18 to 49 years of age:&#xD;
&#xD;
          -  Body mass index (BMI) from ≥18 kg/m^2 and ≤35 kg/m^2&#xD;
&#xD;
          -  Female participants must be either of non-childbearing potential or if of childbearing&#xD;
             potential may be enrolled if the participant: 1) has a negative pregnancy test at&#xD;
             Screening and on the day of vaccination, and 2) has practiced adequate contraception&#xD;
             or has abstained from all activities that could lead to pregnancy for 28 days prior to&#xD;
             vaccination, and 3) has agreed to continue adequate contraception through 3 months&#xD;
             following the last vaccination, and 4) is not currently breastfeeding&#xD;
&#xD;
        Specific inclusion criteria for children 12 to 59 months of age:&#xD;
&#xD;
          -  Seropositive for both hMPV and PIV3 neutralizing antibody at Screening&#xD;
&#xD;
          -  Has received routine immunizations appropriate for age per the Centers for Disease&#xD;
             Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP)&#xD;
&#xD;
          -  Current height and weight above the third percentile for age&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Adult and pediatric participants eligible for this study must not meet any of the following&#xD;
        criteria:&#xD;
&#xD;
          -  Acutely ill or febrile (temperature ≥38.0℃/100.4°F, regardless of route) on the day of&#xD;
             the first vaccination&#xD;
&#xD;
          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care&#xD;
&#xD;
          -  Receipt of, or plans for receipt of an inactivated vaccine(s) 14 days prior to though&#xD;
             14 days following each study injection or a live virus vaccine(s) within 28 days prior&#xD;
             to, or plans to through 28 days following each study injection. The exception is any&#xD;
             COVID-19 vaccine (regardless of type of vaccine) that becomes available to the&#xD;
             participant during the study; efforts should be made to space study vaccinations and&#xD;
             COVID-19 vaccinations by at least 7 and preferably 14 days, but COVID-19 vaccinations&#xD;
             should not be delayed.&#xD;
&#xD;
          -  Any chronic administration of an immunosuppressant or other immune modifying drug&#xD;
&#xD;
          -  Prior administration of investigational agent using lipid nanoparticle formulations&#xD;
&#xD;
          -  Donation of blood or blood products ≥450 mL within 28 days of the Screening visit (for&#xD;
             the Adult Cohort)&#xD;
&#xD;
          -  Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Participated in an interventional clinical trial within 28 days prior to the day of&#xD;
             enrollment, or plans to do so while enrolled in this trial&#xD;
&#xD;
          -  Has a family member or household contact who is an employee of the research center or&#xD;
             otherwise involved with the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Research Associates Inc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UHS Primary Care</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Child Healthcare Associates</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Child Healthcare Assoc.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Assn Inc</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford Children's Hospital</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch (UTMB)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ModernaTX</keyword>
  <keyword>mRNA-1653</keyword>
  <keyword>human metapneumovirus</keyword>
  <keyword>human parainfluenza</keyword>
  <keyword>human parainfluenza vaccine</keyword>
  <keyword>virus diseases</keyword>
  <keyword>RNA virus infections</keyword>
  <keyword>paramyxoviridae infections</keyword>
  <keyword>mononegavirales infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

